HB4409, titled the Fair Pharmacies for Federal Employees Act of 2025, would bar the Office of Personnel Management from contracting with Federal Employees Health Benefits carriers that own, operate, control, or direct any part of a pharmacy. It would also prohibit OPM and FEHB carriers from contracting or subcontracting with pharmacy benefit managers that directly or indirectly own, operate, control, or direct any part of a pharmacy. In effect, the bill seeks to separate pharmacy benefit management from pharmacy ownership in the federal employee health plan market.
The bill defines key terms broadly. “Pharmacy” includes retail, mail-order, specialty, hospital, long-term care, nursing home, infusion, and other pharmacies, while “pharmacy benefit manager” is defined to cover entities that negotiate drug prices and rebates, build and manage pharmacy networks, process claims, handle prior authorizations and appeals, and administer prescription drug benefits, even if they do not label themselves as PBMs. The bill also clarifies that it does not limit the authority of the FTC, DOJ Inspector General, HHS, or state attorneys general under other laws.
If enacted, the bill would change federal procurement and contracting rules for the Federal Employees Health Benefits program by disqualifying carriers and PBMs with common ownership ties to pharmacies. It would likely affect large integrated health and pharmacy companies that participate in FEHB contracts, and could require restructuring of ownership arrangements or contract relationships to remain eligible. The bill does not create a new enforcement regime, but instead makes compliance with the ownership ban a condition of federal contracting and preserves existing federal and state antitrust and enforcement authority.
Based on the bill text and the absence of recorded committee debate or votes, the available record suggests the measure is framed as a competition and conflict-of-interest reform rather than a partisan policy fight. The sponsors’ framing indicates concern about anticompetitive vertical integration in the prescription drug supply chain and its effect on federal employees’ health coverage. No formal vote history or transcript is available here to show broader support or opposition, so sentiment can only be characterized as sponsor-driven and reform-oriented.
The central point of contention is likely the bill’s broad prohibition on common ownership between PBMs and pharmacies, which could be viewed by supporters as necessary to curb conflicts of interest and by opponents as an overbroad restriction on integrated care and business models. Another likely issue is the breadth of the definitions, especially the expansive definition of PBM and the inclusion of many pharmacy types, which could sweep in vertically integrated insurers, pharmacy chains, and specialty drug operations. The bill also leaves open questions about implementation, market disruption, and whether the ownership ban would reduce costs or limit contracting flexibility for FEHB plans.